The Magazine for Sleep Professionals
Friday, July 24, 2026
Axsome Therapeutics, Inc. a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which […]
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]
Takeda announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated […]
Panthera Dental is proud to announce that their abstracts were accepted for poster presentation at the AADSM and for poster and oral presentation at the SLEEP Annual Meetings. The oral presentation is part of a session entitled “Contemporary Management of Sleep Apnea” (O-13). Information regarding the 2025 IIR Grant will […]
Nightmares are not just a fleeting inconvenience—they can have profound implications on mental health and overall well-being. Recent studies have suggested that nightmares are underdiagnosed and undertreated, even in sleep centers.1,2 Because it is unlikely that patients will report nightmares without provocation, it is important for providers to inquire about […]
K Pharmaceuticals has announced the launch of Aquoral, a clinically proven oral spray for dry mouth. Also known as xerostomia, it is a common, sometimes debilitating condition caused by disease, medication side effects, or other factors that result in discomfort or pain and may affect the ability to chew, taste, […]
Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating […]
The thought of histamines might conjure up images of itchy hives or the tickling sensation just before a sneeze, but scientists have come to realize there is much more to histamines than their connection to allergies. Recent research reveals that histamines play a vital role in wakefulness. Produced by brain […]
Harmony Biosciences Holdings, Inc. announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 net revenue guidance of $820-$860 million remains unchanged. “We […]
Panthera Dental, a global leader in CAD/CAM implant solutions and dental sleep medical devices, proudly announces the launch of its best-in-class BioMatch System, set to streamline the field of oral appliance therapy (OAT). The BioMatch System is designed to make ordering of a patient-matched appliance an effortless process, ease dental […]
